SPATA19 and neoplasm: Consistent with the timing of peak SPAS-1+ response in blood, the frequency of SPAS-1+ cells was also amplified at day 14 in both the spleen (Fig. 6a, b) and tumor (Fig. 6a, c) of dual therapy mice.